Researchers from Ben-Gurion University and Teva have developed an improved version of an experimental medicine for the treatment of the chronic skin disease psoriasis. It inhibits the faulty immune system signal interleukin-17 that triggers the inflammation associated with psoriasis.
http://www.israelhayom.com/site/newsletter_article.php?id=7591